Elysium Health is a health company co-founded by MIT scientist Dr. Leonard Guarente and composed of world-class scientific minds who have backgrounds from some of the most prestigious academic institutions around the world. The company’s goal is to translate advancements in science and technology intoclinically-validated health products that work..
To ensure that Basis works as intended, Elysium Health put the supplement through a clinical trial. During the trial, 120 subjects were divided into three even groups. The first group received the recommended daily dose of Basis, two capsules. The second group received double the recommended daily dose of Basis, four capsules. The third group received a placebo. The results of the trial showed that taking the recommended daily dose of Basis increased levels of NAD+ by an average of 40 percent over the course of several weeks.
Basis is vegetarian, vegan, nut-free, and gluten-free, allowing you to stick to your dietary needs while taking the supplement.
Basis is available for purchase on Elysium Health’s website. Each jar of Basis contains 60 capsules, which is enough for 30 days’ worth of daily intake. As a result, the company sells the supplement in a variety of monthly subscriptions. A regular month-to-month subscription costs $50 each month. The most popular plan is the six-month subscription to Basis for $270, which breaks down to $45 per month. A one-year subscription to Basis costs $480, or $40 per month. Individual jars cost $60 each.
Elysium is developing new products that focus on the microbiome, cognitive health, skin health, muscle function, and circadian rhythms. These products are in various stages of pre-clinical and clinical trials.
Amicus Therapeutics is a biotechnology company that was founded in 2002 in Cranbury, New Jersey. Its specialty is in advance therapy for a broad range of rare genetic diseases. Things like mutated proteins are studied at the company, and enzyme replacement therapy products are developed for many disorders like Fabry disease and Pompe disease, which are what is known as Lysososmal Storage Disorders, or LSDs.
The drug Galafold was developed by the company, and it is being used by over 100 patients for the treatment of these LSDs. Most of the users of the drug are in Germany, but it is also being introduced in places like France. Italy and the United Kingdom. Galafold helped Amicus Therapeutics generate enough sales to put the company on the New York Stock Exchange. Its NASDAQ trading name is FOLD. Know more about Amicus Therapeutics on dialdish.com.
In 2007, the company went public, and by 2008, it had expanded from just having one location in New Jersey to having another research site in San Diego, California. The Michael J. Fox Foundation gave Amicus Therapeutics a $500,000 grant in 2010 to support their studies on rare and orphan diseases. The company also received a grant from the Alzheimer’s Drug Discovery Foundation in the amount of $210,300 to further their research on Alzheimer’s Disease.
Led by CEO John Francis Crowley and President Bradley L. Campbell, Amicus Therapeutics acquired another company called Scioderm in 2015. Scioderm also specialized in treating rare diseases through biotechnology methods, which is defined as simply being technology that’s based on biology. Know more on gcreport.com about Amicus Therapeutics.
There are currently more than 200 biotechnology health care products and vaccines on the market, and many of them are being used to treat diseases that were once deemed untreatable. Amicus Therapeutics works to provide help for patients who have these types of rare diseases by continuing to create effective medicinal treatments.
It was recently announced that innovative medical company Tempus has raised more than $70 million in funds. The funds came from two core investors in the series C round, New Enterprise Associates and Investors Revolution Growth. Overall, Tempus has raised more than $130 million in three separate rounds of funding. This has all been raised since the company started in just 2015, launching it from a small medical startup to a top game changer in the field of cancer diagnostics. According to a recent article in Forbes Magazine, this brings the total valuation of Tempus to about $700 million dollars.
Tempus was co-founded by Eric Lefkofsky, who is a serial entrepreneur that also founded Groupon. He currently serves as Tempus’s Chief Executive Officer. Tempus is a rapidly growing technology company that focuses on data driven cancer care. It is a complete informational system that is seeking to become the world’s largest data base of cancer information.
Lefkofsky founded Tempus after realizing that although there is a mass of data about cancer treatment and research methods there was no singular operating system that allowed doctors to access that data. Most of the information was contained in physicians notes that were filed away at individual hospitals rather than a central system. Tempus is seeking to change all that by centralizing the data and information.
Lefkofsky’s vision is to utilize the power of technology to complete this process. This is incredibly beneficial for the cancer patients who can benefit from this information being in the hands of their oncologists and the team. Cancer care becomes completely personal with access to this multitude of information. Research gained from one patient can be accessed by an oncologist on the other side of the country in real time. Additionally, Tempus is scaling its Business to Business partnership. In 2016 they have partnered with the Cleveland Clinic, the Mayo Clinic and Duke University. Tempus continues to grow and scale, with more and more partnerships in the works for 2017 and beyond.
With his competitive nature and drive for success, Logan Stout has gone to some amazing places in life. Logan Stout has leveraged his God-given abilities, not only for his own personal success but also to help others realize their potential as well. His passion for life is contagious to those around him and it is also reflected in his company IDLife.
Logan Stout was ambitious in high school whether it was academics or athletics. He was successful and received awards in both endeavors. Although he’s more known for baseball, while in high school he was a basketball standout. Twice he was awarded the MVP award for his district. He was a member of the Varsity squad in baseball and basketball throughout his time in high school. He also took on a leadership role when he was elected to the Student Athletic Council. This was based on his excellence as an athlete, his leadership skills, and classroom achievements.
After high school, Stout chose to focus on baseball. He excelled as a college player, and he received several awards. His passion for baseball took him into the professional ranks where he played two seasons with a minor league squad called the Fort Worth Cats. All of this helped lead him to his next undertaking which consisted of coaching and mentoring.
Stout founded the Dallas Patriots baseball organization. Here his service to others and his entrepreneurial bent merged to form a unique opportunity for kids. The Patriots offer one-on-one coaching, baseball clinics, and the chance to grow skills and confidence. They have become one of the largest organizations of this kind.
Stout also has a book credit under his belt with his “Stout Advice: The Secrets to Building Yourself, People, and Teams”. He enjoys success as an inspirational speaker as well.
Logan Stout’s latest project fits the mold of prior initiatives which help people achieve their potential. This time he’s ventured into health and wellness. With an emphasis on education, IDLife provides high-quality natural supplements to positively impact one’s health.
An innovative aspect of their business is IDLife’s customization program for each customer. By providing information on their health and personal habits, customers are able to access a tailored approach unique unto themselves. IDLife’s personalized approach is exceptional in the health and wellness realm.
Visit idlife.com for more information about Logan Stout and his company.